| | | Margulis et al., 2009 [4] | Yohannan et al., 2010 [21] | El Hajj et al., 2013 [22] | Paparel et al., 2014 [16] | Russell et al., 2014 [17] | Thomas et al., 2015 [18] |
| | Number () | 54 | 4 | 9 | 72 | 22 | 102 |
| | Fuhrman grade of primary tumor () | Grade 1, 0
Grade 2, 10
Grade 3, 21
Grade 4, 23 | Grade 2, 1
Grade 3, 3 | Grade 1, 0
Grade 2, 1
Grade 3, 4
Grade 4, 1
Not reported, 3 | Grades 1, 0
Grade 2, 2
Grade 3, 35
Grade 4, 15
Unclassified, 7 | NR | Grades 1-2, 28
Grades 3-4, 74 |
| | T stage of primary tumor () | T1, 10
T2, 11
T3, 33
T4, 0 | T1, 1
T2, 2
T3, 1 | Tx, 3
T1, 3
T2, 1
T3, 2
T4, 0 | Tx, 2
T1, 21
T2, 13
T3, 32
T4, 4 | T1, 6
T2, 4
T3, 12
T4, 0 | T1, 20
T2, 20
T3, 59
T4, 3 |
| | Mean/median age at time of recurrence (yrs.) | NR | 57 | 67 | NR | 62 | 55 |
| | Mean/median time to recurrence (mos.) | 10 | 11.5 | 83 | 26.5 ± 3.3 | 31.5 | 19 |
| | Mean/median size of recurrence (cm) | 6 | 5.7 | 3.4 | 4.7 ± 0.5 | 2.6 | 4.5 |
| | Neoadjuvant therapy () | 27 | NR | 3 | 2 | 3 | 46 |
| | Surgical approach for recurrence surgery () | Open | Laparoscopic | Laparoscopic | Open, 47
Laparoscopic, 1 | Open, 21
Laparoscopic, 1 | Open, 99
Laparoscopic 3 |
| | Mean/median operative time (min.) | 377.5 | 195 | 144 | 133.2 | NR | 210 |
| | Mean/median estimated blood loss (mL) | 600 | 187.5 | 430 | 427.5 | 300 | 700 |
| | Mean/Median length of hospital stay (day) | 7 | 2.5 | 4.5 | NR | 5 | 7 |
| | Positive surgical margin () | NR | 0 | 0 | NR | 1 | 12 |
| | Complications () | Clavien 3 and 4, 8 | Clavien 1, 1 | Clavien 1, 3
Claiven 3b, 1 | Clavien 2, 2
Clavien 3a, 5
Clavien 3b, 3
Clavien 4, 3 | Clavien 3b, 2 | Clavien 1, 16
Clavien 2, 15
Clavien 3, 12
Clavien 4, 1 |
| | Perioperative mortality () | 2 | 0 | 0 | 1 | 0 | 2 |
| | Adjuvant therapy after recurrence surgery () | 16 | NR | 2 | 0 | Targeted therapy, 2
Radiotherapy, 1 | 48 |
| | Follow-up (months) | NR | 38 | 38 | 51.7 ± 4.3 | 22.2 | 32 |
| | Survival data | Cancer specific survival: 11 months | Disease free survival: 75%
Cancer specific survival: 100% | Disease free survival: 67%
Cancer specific survival: 89% | Cancer specific mortality: 39% | Median progression free survival: 12.7 months | Median progression free survival: 23 months
Median cancer specific survival: 66 months |
|
|
